6-methoxy-1-oxo-2,3-dihydro-1H-inden-5-yl trifluoromethanesulfonate | 760992-96-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 6-methoxy-1-oxo-2,3-dihydro-1H-inden-5-yl trifluoromethanesulfonate
• 英文别名: (6-Methoxy-1-oxo-2,3-dihydroinden-5-yl) trifluoromethanesulfonate；(6-methoxy-1-oxo-2,3-dihydroinden-5-yl) trifluoromethanesulfonate
• CAS: 760992-96-9
• 化学式: C₁₁H₉F₃O₅S
• 分子量: 310.251
• InChiKey: OYRYKVZZYQHBCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  甲醇 、 6-methoxy-1-oxo-2,3-dihydro-1H-inden-5-yl trifluoromethanesulfonate 、 一氧化碳 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 三乙胺 作用下， 110.0 ℃ 、3.45 MPa 条件下， 反应 16.0h， 以77%的产率得到methyl 6-methoxy-1-oxoindane-5-carboxylate
  参考文献：
  名称：

  [EN] FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS
  [FR] INHIBITEURS DE PYRAZOLE KINASE FUSIONNEE TRICYCLIQUE ET TETRACYCLIQUE

  摘要：

  具有化学式(I) (I)的化合物对抑制蛋白激酶很有用。还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。

  公开号：

  WO2004080973A1
• 作为产物：
  描述：

  5-羟基-6-甲氧基-1-茚满酮 、 三氟甲磺酸酐 在 2,6-二甲基吡啶 、 4-二甲氨基吡啶 作用下， 以94%的产率得到6-methoxy-1-oxo-2,3-dihydro-1H-inden-5-yl trifluoromethanesulfonate
  参考文献：
  名称：

  [EN] FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS
  [FR] INHIBITEURS DE PYRAZOLE KINASE FUSIONNEE TRICYCLIQUE ET TETRACYCLIQUE

  摘要：

  具有化学式(I) (I)的化合物对抑制蛋白激酶很有用。还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。

  公开号：

  WO2004080973A1

文献信息

• Fused tri and tetra-cyclic pyrazole kinase inhibitors
  申请人：——

  公开号：US20040259904A1

  公开（公告）日：2004-12-23

  Compounds having the formula (I) 1 are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  化合物具有公式（I）1，对于抑制蛋白激酶具有用途。还公开了制备该化合物的方法，含有该化合物的组合物以及使用该化合物的治疗方法。
• Discovery of 4′-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4′-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2′-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors
  作者：Zhi-Fu Tao、Gaoquan Li、Yunsong Tong、Kent D. Stewart、Zehan Chen、Mai-Ha Bui、Philip Merta、Chang Park、Peter Kovar、Haiying Zhang、Hing L. Sham、Saul H. Rosenberg、Thomas J. Sowin、Nan-Horng Lin

  DOI：10.1016/j.bmcl.2007.07.102

  日期：2007.11

  An extensive structure-activity relationship study of the 3-position of a series of tricyclic pyrazole-based Chk1 inhibitors is described. As a result, 4'-,1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles (4) and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)pyridine-2'-carbonitriles (29) emerged as new lead series. Compared with the original lead compound 2, these new leads fully retain the biological activity in both enzymatic inhibition and cell-based assays. More importantly, the new leads 4 and 29 exhibit favorable physicochemical properties such as lower molecular weight, lower Clog P, and the absence of a hydroxyl group. Furthermore, structure-activity relationship studies were performed at the 6- and 7-positions of 4, which led to the identification of ideal Chk1 inhibitors 49, 50, 51, and 55. These compounds not only potently inhibit Chk1 in an enzymatic assay but also significantly potentiate the cytotoxicity of DNA-damaging agents in cell-based assays while they show little single agent activity. A cell cycle analysis by FACS confirmed that these Chk1 inhibitors efficiently abrogate the G2/M and S checkpoints induced by DNA-damaging agent. The current work paved the way to the identification of several potent Chk1 inhibitors with good pharmacokinetics that are suitable for in vivo study with oral dosing. (c) 2007 Elsevier Ltd. All rights reserved.
• FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS
  申请人：ABBOTT LABORATORIES

  公开号：EP1603885A1

  公开（公告）日：2005-12-14
• US7320986B2
  申请人：——

  公开号：US7320986B2

  公开（公告）日：2008-01-22
• [EN] FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRAZOLE KINASE FUSIONNEE TRICYCLIQUE ET TETRACYCLIQUE
  申请人：ABBOTT LAB

  公开号：WO2004080973A1

  公开（公告）日：2004-09-23

  Compounds having the formula (I) (I), are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有化学式(I) (I)的化合物对抑制蛋白激酶很有用。还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。